Positions
- Associate Professor
-
Department of Pathology & Immunology
Baylor College of Medicine
Houston, Texas United States
Addresses
- Texas Children's Hospital (Lab)
-
Department of Pathology
1102 Bates Street FC830.20
Houston, TX 77030
United States
Education
- MSc from University of Buenos Aires, School of Clinical Pathology and Pharmacy
- Buenos Aires, Buenos Aires Argentina
- PhD from University of Buenos Aires, School of Clinical Pathology and Pharmacy
- Buenos Aires, Buenos Aires Argentina
- Clinical Pathology
- Postdoctoral Fellowship at National Institutes of Health
- Bethesda, Maryland United States
- Postdoctoral Fellowship at Memorial Sloan-Kettering Cancer Center
- New York, New York United States
Professional Interests
- Genetic regulation of blood formation including the immune system
- Pathobiology and treatment of myeloid and lymphoid leukemia
- Mechanisms of self-renewal in normal and leukemic hematopoietic stem cells
Websites
Selected Publications
- Yamada T, Park CS, Mamonkin M, Lacorazza HD "Transcription factor ELF4 controls the proliferation and homing of CD8+ T cells via the Krüppel-like factors KLF4 and KLF2.." Nat. Immunol.. 2009 Jun;10(6):618-26. Pubmed PMID: 19412182
- Shen Y, Park CS, Suppipat K, Mistretta TA, Puppi M, Horton TM, Rabin K, Gray NS, Meijerink JP, Lacorazza HD. "Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.." Leukemia. 2017; Pubmed PMID: 27872496
- Park, C.S.; Lewis, AH, Chen, TJ, Bridges, CS, Shen, Y, Suppipat, K, Puppi, M, Tomolonis, JA, Pang, PD, Mistretta, TA, Ma, L, Green, MR, Rau, R, Lacorazza, HD "A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells." Blood. 2019 Nov 28;134(22):1960-1972. Pubmed PMID: 31515251
- Bridges CS, Chen TJ, Puppi M, Rabin KR, Lacorazza HD "Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia." Blood Advances. 2023 Feb 14;7(3):422-435.
- Kim, Orr, Kwong, Deibler, Munshi, Bridges, Chen, Zhang, Lacorazza, Scheidt "Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors." ACS Med Chem Lett. 2023 Apr 17;14(5):606-613.
Funding
- Targeting DYRK2 stability to eradicate leukemia stem cells in chronic myeloid leukemia - #R01 CA283079-01A1 Grant funding from National Cancer Institute
- A molecular approach to dissecting MEK-mediated phosphorylation in pediatric leukemia - #R01 CA285402-01A1 Grant funding from National Cancer Institute
- Discovery of MAP2K7 Inhibitors Through DNA-Encoded Chemical Screens to Treat T-Cell Acute Lymphoblastic Leukemia - #1R21CA286412-01A1 Grant funding from National Cancer Institute
Log In to edit your profile